Bevacizumab Cheaper Than Ranibizumab for Macular DegenerationBevacizumab Cheaper Than Ranibizumab for Macular Degeneration

Cost analysis favors one vascular endothelial growth factor inhibitor over another for patients with age-related macular degeneration. Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Ophthalmology News Source Type: news